COVID-19 Vaccine Providers Newsletter 09.07.2022


  • FDA Authorizes Moderna and Pfizer-BioNTech Bivalent COVID-19 Boosters
    • On August 31, 2022, the U.S. Food and Drug Administration (FDA) amended the emergency use authorizations (EUAs) of the Moderna and Pfizer-BioNTech COVID-19 Vaccines to authorize bivalent formulations of the vaccines for use as a single-booster dose at least two months following primary or booster vaccination.
    • On September 1,2022, the Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) reviewed information about Pfizer’s and Moderna’s COVID-19 updated bivalent vaccines. They recommended that both be placed into general public use.
    • The Pfizer and Moderna bivalent COVID-19 vaccines contain components from the original SARS-CoV-2 virus and spike protein components from the Omicron BA.4 and BA.5 subvariants. These new booster vaccines are referred to as “updated boosters.”
    • Following ACIP’s meeting,  the CDC endorsed ACIP’s recommendations for the use of updated COVID-19 bivalent boosters. Pfizer-BioNTech’s bivalent booster is authorized for people aged 12 years and older and Moderna’s updated booster for people aged 18 years and older.
    • Per the updated EUAs, Pfizer’s and Moderna’s monovalent mRNA COVID-19 vaccines are no longer authorized for use as boosters in people ages 12 years and older.
    • The bivalent booster recommendation replaces previous booster recommendations for people aged 12 years and older. As a result, all existing appointments for monovalent Pfizer-BioNTech or Moderna boosters in people 12 years of age and older should be rescheduled for a date and time when locations have the bivalent booster vaccine available.
    • At this time, there are no changes to COVID-19 vaccination schedules for children ages 6 months through 11 years
  • Novavax COVID-19 for Adolescents: Updated Recommendations
    • On August 22, 2022, CDC Director Dr. Walensky signed a decision memo that Novavax’s COVID-19 vaccine be used as another primary series option for adolescents aged 12 through 17 years. This recommendation follows FDA’s emergency use authorization of the Novavax vaccine for this age group.
    • Novavax’s COVID-19 vaccine, which is available now, is an important tool in the pandemic and provides a more familiar type of COVID-19 vaccine technology for adolescents. Having multiple types of vaccines offers more options and flexibility for the public, jurisdictions, and vaccine providers.
    • CDC’s Interim Clinical Considerations for Use of COVID-19 Vaccines has been updated with new guidance regarding adolescents and Novavax COVID-19 vaccine.
  • Moderna (Spikevax) COVID-19 Vaccine Available for Ordering
    • The Moderna (Spikevax) COVID-19 vaccine received FDA approval in January 2022, for administration to people ages 18 years and older. Similar to Comirnaty, Spikevax is licensed through the Biologics License Applications (BLA) process.
    • The FDA-authorized Moderna COVID-19 vaccine for individuals ages 18 years and older will now be marketed as Spikevax. Ordering for Spikevax began in August 2022.
    • The FDA-approved Spikevax and the EUA Moderna COVID-19 vaccine for people ages 12 years and older have the same formulation and can be used interchangeably

Significant Changes to CDC Guidance or Materials

  • (Updated) Interim Clinical Considerations for use of COVID-19 Vaccines. CDC has updated its vaccination recommendations to include:
    • New booster recommendation for people aged 12 years and older to receive 1 bivalent mRNA booster after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group.
      • Recommendations for use of a bivalent Moderna booster dose in people ages 18 years and older
      • Recommendations for use of a bivalent Pfizer-BioNTech booster dose in people aged 12 years and older
    • Updated guidance for observation periods following COVID-19 vaccination
    • Updated guidance on COVID-19 vaccination and Multi-system Inflammatory Syndrome in children (MIS-C) and adults (MIS-A)


  • Notable revisions to the updated Virginia guidance include:
    • Updated testing guidance for persons who test positive for COVID-19 and are unable or choose not to wear a mask through day 10. Recommendations to either isolate for 10 full days (including children under age 2) or use the CDC's test-based strategy that includes two negative tests 48 hours apart.
    • Updated testing guidance for persons who have had recent or suspected exposure to an infected person. Guidance for exposed persons is no longer based on vaccination status. Persons who have had recent exposure may consider testing for COVID-19 ≥5 days after exposure (or sooner, if they are symptomatic), regardless of their vaccination status. “Test to Stay” is no longer routinely recommended. Schools that choose to implement Test to Stay programs can contact VDH for more information on available testing resources and/or guidance.
  • For questions about VaxMaX and its functionality, please visit the VaxMaX Help websitewhich includes reference guides and tutorial videos.

Best Practice Spotlight

Upcoming Events

Helpful Resources

Refer to Previously posted resources

Information about the COVID-19 vaccination program is changing frequently. This newsletter will offer regular updates to providers who have submitted an intent to vaccinate or signed the CDC provider agreement within Virginia.

VDH COVID-19 Vaccination Response: Healthcare Professionals Website